scFv(MSLN)-CD28-41BB-CD3zeta CAR-T Lentivirus

scFv(MSLN)-CD28-41BB-CD3ζ CAR-T Lentivirus is a gene-delivery reagent designed to generate T cells that recognize mesothelin (MSLN), a cell-surface glycoprotein overexpressed in several solid tumors. The encoded third-generation chimeric antigen receptor contains an extracellular anti-MSLN single-chain variable fragment (scFv), membrane-anchoring elements, tandem intracellular costimulatory domains from CD28 and 4-1BB (CD137), and the CD3ζ activation domain. The scFv enables antibody-like recognition of surface MSLN without requiring major histocompatibility complex presentation. Following antigen engagement, CD3ζ initiates T-cell activation, while CD28 and 4-1BB provide complementary costimulatory signals associated with effector function, proliferation, survival, and persistence. Lentiviral delivery supports efficient gene transfer and stable CAR expression in transduced T cells, offering a practical platform for studying how dual costimulation shapes MSLN-directed immune responses.

This product is intended for research on mesothelin-targeted cellular immunotherapy and the functional evaluation of third-generation CAR-T cells. Transduced cells can be examined for receptor expression, MSLN-dependent activation, target-cell killing, cytokine secretion, expansion, survival, memory differentiation, and exhaustion. Comparisons among MSLN-high, MSLN-low, and MSLN-negative target cells can help define antigen-density requirements, selectivity, and potential on-target effects across different expression levels. The resulting cells are suitable for appropriately designed studies involving malignant mesothelioma, pancreatic cancer, ovarian cancer, lung cancer, and other MSLN-expressing solid-tumor models. This construct also provides a useful reference for comparing dual-costimulatory signaling with first-generation CD3ζ-only receptors or second-generation CARs containing either CD28 or 4-1BB. Additional applications include examining shed mesothelin, repeated antigen exposure, tumor-cell resistance, immune escape, and CAR-T-cell performance under immunosuppressive conditions.